| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.6 |
| mRNA | XL765 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | BRD-K41334119 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.6 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | -0.028 | 0.6 |
| mRNA | CHM-1 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.6 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | A-804598 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.6 |